1-4 of 4
Rainer Schwerdtfeger, PD.
Close
Sort by
Journal Articles

Improved Survival with Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

Michael Schleuning, Christoph Schmid, Christian Koenecke, Bernd Hertenstein, Herrad Baurmann, Rainer Schwerdtfeger, PD, Hans-Jochem Kolb
Journal: Blood
Blood (2006) 108 (11): 3661.
https://doi.org/10.1182/blood.V108.11.3661.3661
Published: 2006
Journal Articles

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, MD, Peter Liebisch, MD, Rainer Schwerdtfeger, PD, Jose Antonio Perez-Simon, MD, Martin Bornhaeuser, PD, Svenja Otterstetter, Judith Dierlamm, PD, Arnon Nagler, Dieter Kurt Hossfeld, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger, PD
Journal: Blood
Blood (2006) 108 (11): 5038.
https://doi.org/10.1182/blood.V108.11.5038.5038
Published: 2006
Journal Articles

Allogeneic-SCT in Patients with Hematological Malignancies Aged 60 Years or Older: Importance of HLA-Matching.

Michael Schleuning, Dirk Judith, Joerg Kaltenhaeuser, Herrad Baurmann, Rainer Schwerdtfeger, PD
Journal: Blood
Blood (2005) 106 (11): 5360.
https://doi.org/10.1182/blood.V106.11.5360.5360
Published: 2005
Journal Articles

Durable Remission after Prophylactic Donor Lymphocyte Transfusion Following Allogeneic Stem Cell Transplantation with Reduced Conditioning for High-Risk AML and MDS.

Michael Schleuning, Christoph Schmid, Georg Ledderose, Johanna Tischer, Meike Humann, Johanna Ullmann, Rainer Schwerdtfeger, PD., Hans-Jochem Kolb
Journal: Blood
Blood (2004) 104 (11): 299.
https://doi.org/10.1182/blood.V104.11.299.299
Published: 2004